Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tracks odevixibat safety for moms and babies

NCT ID NCT06258902

Recruiting now Knowledge-focused Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 32 times

Summary

This study follows up to 20 people of any age who took the drug odevixibat while pregnant or breastfeeding. Researchers will collect routine medical data to see if the drug is linked to birth defects, pregnancy complications, or harm to the baby. No extra tests or visits are required—only information already recorded by doctors is used.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program

    RECRUITING

    Wilmington, North Carolina, 28401, United States

Conditions

The condition(s) this trial relates to.

Breast Feeding pregnancy disorder Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.